AEON Biopharma AEON 深 沪
交易中 11-06 10:35:34 美东时间
0.1604
+0.002
+1.45%
华盛通- 最 高0.1626
- 今 开0.1601
- 成交量 23.49万股
- 最 低 0.1587
- 昨 收 0.1581
- 总市值 947.72万
- 52周最高 1.45
- 市盈率 静 --
- 换手率 0.40%
- 52周最低 0.1271
- 委 比 -33.33%
- 总股本 5908.47万
- 历史最高 1236.24
- 量 比 0.85
- 振 幅 2.47%
- 历史最低 0.1271
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AEON Biopharma shares are trading lower after the company reduced the exercise price of its two-year warrants from $0.32 to $0.20.
AEON Biopharma shares are trading lower after the company reduced the exercise price of its two-year warrants from $0.32 to $0.20.
11-04 02:26
AEON Biopharma Amends Warrants With Reduced Exercise Prices
AEON Biopharma ( ($AEON) ) just unveiled an announcement. On November 2, 2026, ...
11-03 22:23
AEON Biopharma收跌0.36%，成交额9.16万美元
11月3日，AEON Biopharma（AEON）收跌0.36%，报0.27美元，成交额9.16万美元，市值1613.01万美元。 行情数据 • 开盘价：0...
11-03 08:49
AEON Biopharma收涨0.04%，成交额2.67万美元
10月27日，AEON Biopharma（AEON）收涨0.04%，报0.24美元，成交额2.67万美元，市值1197.19万美元。 行情数据 • 开盘价：...
10-27 07:56
AEON Biopharma Posts Updated Investor Presentation Under Reg FD
AEON Biopharma ( ($AEON) ) has issued an update. On October 23, 2026, AEON Biop...
10-24 04:52
AEON Biopharma收跌4.53%，成交额5.9万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 08:01
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
AEON Biopharma granted 150,000 RSUs to a new non-executive employee, vesting 25% annually over four years, under its 2025 Employment Inducement Incentive Award Plan. The company focuses on developing ABP-450, a biosimilar to BOTOX, targeting the $3 billion U.S. therapeutic neurotoxin market. ABP-450 is manufactured by Daewoong Pharmaceutical and approved for cosmetic use as Jeuveau. AEON holds exclusive rights for therapeutic indications in key m...
10-09 20:15
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
AEON Biopharma shares are trading higher after the company announced that the FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX may be submitted as supportive evidence.
AEON Biopharma shares are trading higher after the company announced that the FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX may be submitted as supportive evidence.
10-01 02:13
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
AEON Biopharma announced progress in developing ABP-450, a biosimilar to BOTOX®, following a Type 2b meeting with the FDA. The FDA supports a streamlined development path, allowing AEON to potentially avoid a standalone comparative efficacy study. The company plans to submit an IND for a CMAP pharmacodynamic study in Q4 2026 and leverage existing comparative human evidence and analytical data to support biosimilarity. AEON aims to reduce clinical...
09-30 12:00
